BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 0.25% on Monday.
The Dow traded up 0.25% to 34,596.04 while the NASDAQ rose 0.92% to 14,243.64. The S&P 500, also rose, gaining, 0.43% to 4,524.74.